ArticleFrontiers in nutrition2026
Lunasin alleviates pulmonary inflammation in A549 alveolar epithelial cells and C57BL6/J mice in obese-mimicking conditions.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity is accompanied by low-grade and chronic pathological development that can worsen pulmonary inflammation and fibrosis. This study investigated the potential of lunasin, a naturally occurring seed peptide with multiple bioactive properties, to attenuate lung inflammation in A549 pulmonary epithelial cells and in C57BL6/J mice fed with the high-fat diet. Methods: Results: Lunasin inhibited PA- or LPS-induced interleukin (IL)-6, monocyte chemoattractant protein (MCP)-1, and transforming growth factor (TGF)-β secretion. While LPS reduced surfactant protein D (SP-D) expression, lunasin restored SP-D by inhibiting the nuclear factor kappa B (NF-κB) signaling pathway. Additionally, pulmonary fibrosis was induced by TGF-β-induced epithelial-mesenchymal transition (EMT), as indicated by reduced vimentin and preserved E-cadherin expression. However, lunasin did not affect the TGF-β-induced EMT marker in A549 cells. Conclusion: In summary,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.